Skip to main content
Erschienen in: Cancer Chemotherapy and Pharmacology 4/2019

28.01.2019 | Original Article

Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP

verfasst von: E. Baudry, S. Huguet, A. L. Couderc, P. Chaibi, F. Bret, C. Verny, S. Weill, O. Madar, S. Urien, Keyvan Rezai

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma in elderly patients, and R-CHOP chemotherapy is the standard treatment protocol for DLBCL. Elderly patients (often defined as 75 years of age) are treated with anticancer drugs with precaution; however, the pharmacokinetics and pharmacodynamics (PK and PD) of these agents have not been thoroughly investigated in this population. In this study, we investigated the PK of cyclophosphamide (CP) and doxorubicin (DOXO) in elderly patients in order to verify if there is an influence of age on the PK of these anticancer drugs.

Materials and methods

This is a prospective multi-center clinical trial investigating the PK of CP and DOXO in elderly and very elderly patients with DLBCL treated by R-mini-CHOP regimen. Dose levels were 25 mg/m2, 0.7–1.4 mg/m2, 750 mg/m2, and 375 mg/m2 for DOXO, Vincristine (VCR), CP, and Rituximab, respectively. For PK analysis, 7 time point samples were collected over 48 h post-administration on cycle 3. CP and VCR plasma concentrations were measured using UPLC–MS/MS validated method. DOX plasma concentrations were measured using UPLC coupled with fluorescence detection-validated method. PK-POP modeling has been performed with a non-linear mixed-effect model program (Monolix).

Results

31 patients (15 males and 16 females), 75 to 96 years old, were treated with R-miniCHOP protocol. Among them, 19 patients were treated with VCR. A one-compartment (1cpt) open model with linear elimination adequately described CP concentration–time courses. The population PK parameters for CP were: CL = 3.58 L/h, Vmale = 32.2 L, and Vfemale = 28.7 L. Body weight (BW), albuminemia, and gender demonstrated a significant impact on CP PK. A 2-compartment (2cpt) open model with linear elimination best described DOXO concentration–time courses. The population PK parameters for DOXO obtained for the structural model were: CL = 51.1 L/h, Q = 49.6 L/h, V1 = 29.4 L, V2 = 1,130 L (clearances: CL, Q, volumes of distribution: V1, V2). The main covariate effects on DOXO PK were related to gender, BW, and VCR administration. VCR increases DOXO V1 from 29.4 L to 57.5 L (p = 0.02). No hematologic and cardiac grade 3 or 4 toxicity were recorded.

Conclusions

Usually, in the absence of specific data, the majority of the physicians empirically reduce anticancer drug dose in the elderly patients (Tourani in J Geriatr Oncol 3(1): 41–48, 2012), or even does not treat these very-old patients. A better knowledge of the pharmacokinetics in very-old patients should allow a better dose adjustment based on the most significant physiological factors that modify the pharmacokinetic parameters. In this study, no serious toxicity was observed in these very elderly patients (84.1 years). This indicates that dose adjustment of chemotherapies should not only be based on age and creatinine clearance, but also, based upon appropriate physiological and biological data. Our findings indicate that, CP dose adjustment should be done according to serum albumin levels and patients BW and gender.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
5.
Zurück zum Zitat Balducci L, Extermann M (2000) Cancer and aging. An evolving panorama. Hematol Oncol Clin N Am 14(1):1–16 (Review. PubMed PMID: 10680068)CrossRef Balducci L, Extermann M (2000) Cancer and aging. An evolving panorama. Hematol Oncol Clin N Am 14(1):1–16 (Review. PubMed PMID: 10680068)CrossRef
6.
Zurück zum Zitat Balducci L, Extermann M (1997) Cancer chemotherapy in the older patient: what the medical oncologist needs to know. Cancer 80(7):1317–1322 (Review. PubMed PMID: 9317185)CrossRef Balducci L, Extermann M (1997) Cancer chemotherapy in the older patient: what the medical oncologist needs to know. Cancer 80(7):1317–1322 (Review. PubMed PMID: 9317185)CrossRef
8.
Zurück zum Zitat Kasel D, Jetter A, Harlfinger S, Gebhardt W, Fuhr U (2004) Quantification of cyclophosphamide and its metabolites in urine using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 18(13):1472–1478 (PubMed PMID: 15216508)CrossRef Kasel D, Jetter A, Harlfinger S, Gebhardt W, Fuhr U (2004) Quantification of cyclophosphamide and its metabolites in urine using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 18(13):1472–1478 (PubMed PMID: 15216508)CrossRef
9.
Zurück zum Zitat Gilbert CM, McGeary RP, Filippich LJ, Norris RL, Charles BG (2005) Simultaneous liquid chromatographic determination of doxorubicin and its major metabolite doxorubicinol in parrot plasma. J Chromatogr B Anal Technol Biomed Life Sci 826(1–2):273–276 (Epub 2005 Sep 15. PubMed PMID: 16168722)CrossRef Gilbert CM, McGeary RP, Filippich LJ, Norris RL, Charles BG (2005) Simultaneous liquid chromatographic determination of doxorubicin and its major metabolite doxorubicinol in parrot plasma. J Chromatogr B Anal Technol Biomed Life Sci 826(1–2):273–276 (Epub 2005 Sep 15. PubMed PMID: 16168722)CrossRef
10.
Zurück zum Zitat De Baerdemaeker LE, Mortier EP, Struys MM (2004) PK in obese patients. Contin Educ Anaesth Crit Care Pain 4:152–155CrossRef De Baerdemaeker LE, Mortier EP, Struys MM (2004) PK in obese patients. Contin Educ Anaesth Crit Care Pain 4:152–155CrossRef
11.
13.
Zurück zum Zitat Wilde S, Jetter A, Rietbrock S, Kasel D, Engert A, Josting A, Klimm B, Hempel G, Reif S, Jaehde U, Merkel U, Busse D, Schwab M, Diehl V, Fuhr U (2007) Population PK of the BEACOPP polychemotherapy regimen in Hodgkin’s lymphoma and its effect on myelotoxicity. Clin Pharmacokinet 46(4):319–333 (PubMed PMID: 17375983)CrossRef Wilde S, Jetter A, Rietbrock S, Kasel D, Engert A, Josting A, Klimm B, Hempel G, Reif S, Jaehde U, Merkel U, Busse D, Schwab M, Diehl V, Fuhr U (2007) Population PK of the BEACOPP polychemotherapy regimen in Hodgkin’s lymphoma and its effect on myelotoxicity. Clin Pharmacokinet 46(4):319–333 (PubMed PMID: 17375983)CrossRef
14.
Zurück zum Zitat Joerger M, Huitema AD, Richel DJ, Dittrich C, Pavlidis N, Briasoulis E, Vermorken JB, Strocchi E, Martoni A, Sorio R, Sleeboom HP, Izquierdo MA, Jodrell DI, Féty R, de Bruijn E, Hempel G, Karlsson M, Tranchand B, Schrijvers AH, Twelves C, Beijnen JH, Schellens JH (2007) EORTC-PAMM-NDDG. Population PK and PD of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG. Clin Pharmacokinet 46(12):1051–1068 (PubMed PMID: 18027989)CrossRef Joerger M, Huitema AD, Richel DJ, Dittrich C, Pavlidis N, Briasoulis E, Vermorken JB, Strocchi E, Martoni A, Sorio R, Sleeboom HP, Izquierdo MA, Jodrell DI, Féty R, de Bruijn E, Hempel G, Karlsson M, Tranchand B, Schrijvers AH, Twelves C, Beijnen JH, Schellens JH (2007) EORTC-PAMM-NDDG. Population PK and PD of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG. Clin Pharmacokinet 46(12):1051–1068 (PubMed PMID: 18027989)CrossRef
15.
Zurück zum Zitat Piscitelli SC, Rodvold KA, Rushing DA, Tewksbury DA (1993) PK and PD of doxorubicin in patients with small cell lung cancer. Clin Pharmacol Ther 53(5):555–561 (PubMed PMID: 8387903)CrossRef Piscitelli SC, Rodvold KA, Rushing DA, Tewksbury DA (1993) PK and PD of doxorubicin in patients with small cell lung cancer. Clin Pharmacol Ther 53(5):555–561 (PubMed PMID: 8387903)CrossRef
16.
Zurück zum Zitat Sweatman TW, Lokich JJ, Israel M (1989) Clinical pharmacology of continuous infusion doxorubicin. Ther Drug Monit 11(1):3–9 (PubMed PMID: 2911850)CrossRef Sweatman TW, Lokich JJ, Israel M (1989) Clinical pharmacology of continuous infusion doxorubicin. Ther Drug Monit 11(1):3–9 (PubMed PMID: 2911850)CrossRef
17.
Zurück zum Zitat Rudek MA, Sparreboom A, Garrett-Mayer ES, Armstrong DK, Wolff AC, Verweij J, Baker SD (2004) Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy. Eur J Cancer 40(8):1170–1178 (PubMed PMID: 15110880)CrossRef Rudek MA, Sparreboom A, Garrett-Mayer ES, Armstrong DK, Wolff AC, Verweij J, Baker SD (2004) Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy. Eur J Cancer 40(8):1170–1178 (PubMed PMID: 15110880)CrossRef
18.
Zurück zum Zitat Dobbs NA, Twelves CJ, Gillies H, James CA, Harper PG, Rubens RD (1995) Gender affects doxorubicin PK in patients with normal liver biochemistry. Cancer Chemother Pharmacol 36(6):473–476 (PubMed PMID: 7554038)CrossRef Dobbs NA, Twelves CJ, Gillies H, James CA, Harper PG, Rubens RD (1995) Gender affects doxorubicin PK in patients with normal liver biochemistry. Cancer Chemother Pharmacol 36(6):473–476 (PubMed PMID: 7554038)CrossRef
19.
Zurück zum Zitat Wong AL, Seng KY, Ong EM, Wang LZ, Oscar H, Cordero MT, Copones R, Fan L, Tan SH, Goh BC, Lee SC (2014) Body fat composition impacts the hematologic toxicities and PK of doxorubicin in Asian breast cancer patients. Breast Cancer Res Treat 144(1):143–152. https://doi.org/10.1007/s10549-014-2843-8 (Epub 2014 Jan 31. PubMed PMID: 24481679)CrossRefPubMed Wong AL, Seng KY, Ong EM, Wang LZ, Oscar H, Cordero MT, Copones R, Fan L, Tan SH, Goh BC, Lee SC (2014) Body fat composition impacts the hematologic toxicities and PK of doxorubicin in Asian breast cancer patients. Breast Cancer Res Treat 144(1):143–152. https://​doi.​org/​10.​1007/​s10549-014-2843-8 (Epub 2014 Jan 31. PubMed PMID: 24481679)CrossRefPubMed
20.
Zurück zum Zitat Li J, Gwilt PR (2003) The effect of age on the early disposition of doxorubicin. Cancer Chemother Pharmacol 51(5):395–402 (Epub 2003 Apr 1. PubMed PMID: 12679882)PubMed Li J, Gwilt PR (2003) The effect of age on the early disposition of doxorubicin. Cancer Chemother Pharmacol 51(5):395–402 (Epub 2003 Apr 1. PubMed PMID: 12679882)PubMed
21.
Zurück zum Zitat Safa AR, Roberts S, Agresti M, Fine RL (1994) Tamoxifen aziridine, a novel affinity probe for P-glycoprotein in multidrug resistant cells. Biochem Biophys Res Commun 202(1):606–612 (PubMed PMID: 7913604)CrossRef Safa AR, Roberts S, Agresti M, Fine RL (1994) Tamoxifen aziridine, a novel affinity probe for P-glycoprotein in multidrug resistant cells. Biochem Biophys Res Commun 202(1):606–612 (PubMed PMID: 7913604)CrossRef
22.
Zurück zum Zitat Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39:361–398 (Review. PubMed PMID: 10331089)CrossRef Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39:361–398 (Review. PubMed PMID: 10331089)CrossRef
23.
Zurück zum Zitat Tourani JM, Mourey L, Servent V, Nguyen T, Ravaud A, Girre V, Favrel S, Pinel MC, Isambert N (2012) Influence of age on the PK of i.v. vinflunine: results of a phase I trial in elderly cancer patients. J Geriatr Oncol 3(1):41–48 (ISSN 1879-4068)CrossRef Tourani JM, Mourey L, Servent V, Nguyen T, Ravaud A, Girre V, Favrel S, Pinel MC, Isambert N (2012) Influence of age on the PK of i.v. vinflunine: results of a phase I trial in elderly cancer patients. J Geriatr Oncol 3(1):41–48 (ISSN 1879-4068)CrossRef
Metadaten
Titel
Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP
verfasst von
E. Baudry
S. Huguet
A. L. Couderc
P. Chaibi
F. Bret
C. Verny
S. Weill
O. Madar
S. Urien
Keyvan Rezai
Publikationsdatum
28.01.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
Cancer Chemotherapy and Pharmacology / Ausgabe 4/2019
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-019-03775-9

Weitere Artikel der Ausgabe 4/2019

Cancer Chemotherapy and Pharmacology 4/2019 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.